Matinas BioPharma Holdings, Inc.
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
MTNB | NYSE
Overview
Corporate Details
- ISIN(s):
- US5768101058
- LEI:
- Country:
- United States of America
- Address:
- 1545 ROUTE 206 SOUTH, 7921 BEDMINSTER
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing novel products to address unmet medical needs. The company's core technology is its proprietary Lipid Nano-Crystal (LNC) platform, which enables the safe, oral, and intracellular delivery of small molecules, nucleic acids, and other therapeutics. Its lead product candidate, MAT2203, is an oral formulation of the anti-fungal drug amphotericin B. In addition to infectious diseases, Matinas is pursuing discovery programs using its LNC platform for applications in oncology and inflammation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Matinas BioPharma Holdings, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Matinas BioPharma Holdings, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Matinas BioPharma Holdings, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
